Driehaus reports 4.87% stake in Xenon
Xenon Pharmaceuticals Inc. reports that Driehaus Capital Management LLC beneficially owned 4,491,653 shares of common stock, representing 4.87% of the class as of 12/31/2025.
Rhea-AI Filing Summary
Xenon Pharmaceuticals Inc. reports that Driehaus Capital Management LLC beneficially owned 4,491,653 shares of common stock, representing 4.87% of the class as of 12/31/2025. The amendment is signed by the filer’s General Counsel on 05/15/2026.
The filing lists shared voting and dispositive power for the entire position and classifies the holding as ownership of 5 percent or less of the class.
Positive
- None.
Negative
- None.
Insights
Driehaus holds a stake just under 5% of Xenon, disclosed via an amended Schedule 13G.
The filing shows 4,491,653 shares and 4.87% ownership as of 12/31/2025, with shared voting and dispositive power. This indicates passive institutional ownership reported under beneficial-ownership rules.
Impact depends on future filings or changes in position; subsequent amendments or Schedule 13D triggers would alter the picture.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficially owned regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Driehaus Capital report in Xenon (XENE)?
Does the Schedule 13G/A indicate voting or disposition control?
Is this filing a passive ownership disclosure or an active intent filing?
What date is the ownership figure tied to in the filing?
Who signed the amendment for Driehaus Capital?
AI-generated analysis. How Rhea-AI works. Not financial advice.